Other
Otomycosis
8
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Otomycosis is an early-stage landscape with 8 programs across 3 companies. The most active players are Bayer, Cadence Pharmaceuticals, Novartis. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 13
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
12
clinical trials
Completed9 · 75%
Not yet recruiting1 · 8%
Recruiting1 · 8%
Unknown status1 · 8%
Clinical Trials
Trial Activity
12 trials
Terbinafine Hydrochloride for the Treatment of Otomycosis
Not yet recruiting·—·N/A·NCT07152327·50 enrolled
Antifungal Potential of Moringa Olifera Against Otomycosis
Completed·—·Phase 1·NCT04768829·10 enrolled
Effectiveness of 4% Boric Acid in Distilled Water Versus Clotrimazole Solution in Otomycosis Patients.
Unknown status·—·N/A·NCT04824261·100 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)